Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar typhi Vi polysaccharide

Clinical and Vaccine Immunology

Volumn 17, Issue 3, 2010, Pages 412-419

  Staats, Herman F ^a   Kirwan, Shaun M ^a   Whisnant, Carol C ^b   Stephenson, James L ^b   Wagener, Diane K ^b   Majumder, Partha P ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b RTI INTERNATIONAL   (United States)

^c INDIAN STATISTICAL INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; FLUORESCENT DYE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; POLYSACCHARIDE VACCINE; TYPHOID VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BEAD IMMUNOASSAY; CLINICAL TRIAL; CONJUGATION; CONTROLLED STUDY; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; INDIA; INTERMETHOD COMPARISON; PRIORITY JOURNAL; REPRODUCIBILITY; SALMONELLA ENTERICA; SEROTYPE; SIGNAL NOISE RATIO; TYPHOID FEVER; VACCINATION;

ANTIBODIES, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; INDIA; POLYSACCHARIDES, BACTERIAL; SALMONELLA TYPHI; SALMONELLA VACCINES; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES;

EID: 77649262348     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00354-09     Document Type: Article

References (43)

1. Acharya, I. L., C. U. Lowe, R. Thapa, V. L. Gurubacharya, M. B. Shrestha, M. Cadoz, D. Schulz, J. Armand, D. A. Bryla, B. Trollfors, et al. 1987. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report. N. Engl. J. Med. 317:1101.
2. Acosta, C. J., C. M. Galindo, R. L. Ochiai, M. C. Danovaro-Holliday, A. L. Page, V. D. Thiem, J. K. Park, E. Park, H. Koo, X. Y. Wang, R. Abu-Elyazeed, M. Ali, M. J. Albert, B. Ivanoff, T. Pang, Z. Y. Xu, and J. D. Clemens. 2004. The role of epidemiology in the introduction of vi polysaccharide typhoid fever vaccines in Asia. J. Health Popul. Nutr. 22:240-245.
3. Barra, A., D. Schulz, P. Aucouturier, and J. L. Preud'homme. 1988. Measurement of anti-Haemophilus influenzae type b capsular polysaccharide antibodies by ELISA. J. Immunol. Methods 115:111-117.
4. Biagini, R. E., D. L. Sammons, J. P. Smith, B. A. MacKenzie, C. A. Striley, V. Semenova, E. Steward-Clark, K. Stamey, A. E. Freeman, C. P. Quinn, and J. E. Snawder. 2004. Comparison of a multiplexed fluorescent covalent microsphere immunoassay and an enzyme-linked immunosorbent assay for measurement of human immunoglobulin G antibodies to anthrax toxins. Clin. Diagn. Lab. Immunol. 11:50-55.
5. Biagini, R. E., S. A. Schlottmann, D. L. Sammons, J. P. Smith, J. C. Snawder, C. A. F. Striley, B. A. MacKenzie, and D. N. Weissman. 2003. Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides. Clin. Diagn. Lab. Immunol. 10:744-750.
6. Bradney, C. P., G. D. Sempowski, H.-X. Liao, B. F. Haynes, and H. F. Staats. 2002. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J. Virol. 76:517-524.
7. Canh, D. G., F. Y. Lin, V. D. Thiem, D. D. Trach, N. D. Trong, N. D. Mao, S. Hunt, R. Schneerson, J. B. Robbins, C. Chu, J. Shiloach, D. A. Bryla, M. C. Bonnet, D. Schulz, and S. C. Szu. 2004. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect. Immun. 72:6586-6588.
8. de Voer, R. M., F. R. van der Klis, C. W. Engels, G. T. Rijkers, E. A. Sanders, and G. A. Berbers. 2008. Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides. Clin. Vaccine Immunol. 15:1188-1193.
9. Dizer, U., L. Gorenek, O. Guner, T. Pehlivan, V. Ozguven, and A. Pahsa. 2002. Assessment of the antibody response in 110 healthy individuals who have been subject to Vi capsular polysaccharide vaccine. Vaccine 20:3052-3054.
10. Engels, E. A., M. E. Falagas, J. Lau, and M. L. Bennish. 1998. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 316:110-116.
11. Engels, E. A., and J. Lau. 2000. Vaccines for preventing typhoid fever. Cochrane Database Syst. Rev. 2:CD001261.
12. Ferry, B. L., S. A. Misbah, P. Stephens, Z. Sherrell, H. Lythgoe, E. Bateman, C. Banner, J. Jones, N. Groome, and H. M. Chapel. 2004. Development of an anti-Salmonella typhi Vi ELISA: assessment of immunocompetence in healthy donors. Clin. Exp. Immunol. 136:297-303.
13. Findlay, J. W., and R. F. Dillard. 2007. Appropriate calibration curve fitting in ligand binding assays. AAPS J. 9:E260-E267.
14. Fraser, A., M. Paul, E. Goldberg, C. J. Acosta, and L. Leibovici. 2007. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 25:7848-7857.
15. Hardy, E., M. Ohlin, and M. Llano. 1994. Enhanced ELISA sensitivity using TCA for efficient coating of biologically active lipopolysaccharides or lipid A to the solid phase. J. Immunol. Methods 176:111-116.
16. Jauho, E. S., U. Boas, C. Wiuff, K. Wredstrom, B. Pedersen, L. O. Andresen, P. M. Heegaard, and M. H. Jakobsen. 2000. New technology for regiospecific covalent coupling of polysaccharide antigens in ELISA for serological detection. J. Immunol. Methods 242:133-143.
17. Keddy, K. H., K. P. Klugman, C. F. Hansford, C. Blondeau, and N. N. Bouveret le Cam. 1999. Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization. Vaccine 17:110-113.
18. Keitel, W. A., N. L. Bond, J. M. Zahradnik, T. A. Cramton, and J. B. Robbins. 1994. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 12:195-199.
19. Klugman, K. P., I. T. Gilbertson, H. J. Koornhof, J. B. Robbins, R. Schneerson, D. Schulz, M. Cadoz, and J. Armand. 1987. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet ii:1165-1169.
20. Klugman, K. P., H. J. Koornhof, J. B. Robbins, and N. N. Le Cam. 1996. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14:435-438.
21. Kossaczka, Z., F. Y. Lin, V. A. Ho, N. T. Thuy, P. Van Bay, T. C. Thanh, H. B. Khiem, D. D. Trach, A. Karpas, S. Hunt, D. A. Bryla, R. Schneerson, J. B. Robbins, and S. C. Szu. 1999. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect. Immun. 67:5806-5810.
22. Kroon, F. P., J. T. van Dissel, E. Ravensbergen, P. H. Nibbering, and R. van Furth. 1999. Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-Vi). Vaccine 17:2941-2945.
23. Lal, G., P. Balmer, H. Joseph, M. Dawson, and R. Borrow. 2004. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin. Diagn. Lab. Immunol. 11:272-279.
24. Lees, A., B. L. Nelson, and J. J. Mond. 1996. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14:190-198.
25. Lin, F. Y., V. A. Ho, H. B. Khiem, D. D. Trach, P. V. Bay, T. C. Thanh, Z. Kossaczka, D. A. Bryla, J. Shiloach, J. B. Robbins, R. Schneerson, and S. C. Szu. 2001. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 344:1263-1269.
26. Losonsky, G. A., C. Ferreccio, K. L. Kotloff, S. Kaintuck, J. B. Robbins, and M. M. Levine. 1987. Development and evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic Salmonella typhi carriers. J. Clin. Microbiol. 25:2266-2269.
27. Martins, T. B., T. D. Jaskowski, A. Tebo, and H. R. Hill. 2009. Development of a multiplexed fluorescent immunoassay for the quantitation of antibody responses to four Neisseria meningitidis serogroups. J. Immunol. Methods 342:98-105.
28. McGowen, A. L., L. P. Hale, C. P. Shelburne, S. N. Abraham, and H. F. Staats. 2009. The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine 27:3544-3552.
29. McLachlan, J. B., C. P. Shelburne, J. P. Hart, S. V. Pizzo, R. Goyal, R. Brooking-Dixon, H. F. Staats, and S. N. Abraham. 2008. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat. Med. 14:536-541.
30. Nordone, S. K., J. W. Peacock, S. M. Kirwan, and H. F. Staats. 2006. Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines. AIDS Res. Hum. Retroviruses 22:558-568.
31. Panchanathan, V., S. Kumar, W. Yeap, S. Devi, R. Ismail, S. Sarijan, S. M. Sam, Z. Jusoh, S. Nordin, D. Leboulleux, and T. Pang. 2001. Comparison of safety and immunogenicity of a Vi polysaccharide typhoid vaccine with a whole-cell killed vaccine in Malaysian Air Force recruits. Bull. World Health Organ. 79:811-817.
32. Parry, C. M., T. T. Hien, G. Dougan, N. J. White, and J. J. Farrar. 2002. Typhoid fever. N. Engl. J. Med. 347:1770-1782.
33. Peterfi, Z., and B. Kocsis. 2000. Comparison of blocking agents for an ELISA for LPS. J. Immunoassay 21:341-354.
34. Pickering, J. W., T. B. Martins, R. W. Greer, M. C. Schroder, M. E. Astill, C. M. Litwin, S. W. Hildreth, and H. R. Hill. 2002. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am. J. Clin. Pathol. 117:589-596.
35. Pickering, J. W., T. B. Martins, M. C. Schroder, and H. R. Hill. 2002. Comparison of a multiplex flow cytometric assay with enzyme-linked immunosorbent assay for auantitation of antibodies to tetanus, diphtheria, and Haemophilus influenzae type b. Clin. Diagn. Lab. Immunol. 9:872-876.
36. Robbins, J. B., and R. Schneerson. 2004. Future vaccine development at NICHD. Ann. N. Y. Acad. Sci. 1038:49-59.
37. Selinsky, C. L., V. D. Whitlow, L. R. Smith, D. C. Kaslow, and H. M. Horton. 2007. Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human IgG antibodies to anthrax lethal factor antigen. Biologicals 35:123-129.
38. Skogstrand, K., P. Thorsen, B. Norgaard-Pedersen, D. E. Schendel, L. C. Sorensen, and D. M. Hougaard. 2005. Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology. Clin. Chem. 51:1854-1866.
39. Whitaker, J. A., C. Franco-Paredes, C. del Rio, and S. Edupuganti. 2009. Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemics areas. J. Travel Med. 16:46-52.
40. Wood, W. G. 1991. "Matrix effects" in immunoassays. Scand. J. Clin. Lab. Invest. Suppl. 205:105-112.
41. World Health Organization. 2003. Background document: the diagnosis, treatment and prevention of typhoid fever. WHO/V&B/03.07. http://www.who.int/vaccines-documents/DocsPDF03/www740.pdf.
42. World Health Organization. 2008. Typhoid vaccines: WHO position paper. Wkly. Epidemiol. Rec. 83:49-59.
43. Yoshida, H., Y. Imafuku, and T. Nagai. 2004. Matrix effects in clinical immunoassays and the effect of preheating and cooling analytical samples. Clin. Chem. Lab. Med. 42:51-56.